Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 plus HLX10 in first-line sqNSCLC
NCT04976647Phase 2Unknown
- Sponsor
- Henlius
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab in squamous cell carcinoma of the lung (SCCL), sponsored by Henlius. Status: unknown.
02
Drugs
pimurutamab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT04976647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976647.